Journal of Nanomedicine & Nanotechnology

Antioxidant activity and golobe level anticancer (Zingiberaceae) and leaves pangi

2^nd International Conference and Exhibition on Pharmaceutical Nanotechnology & Nanomedicine

March 20 - 21, 2019 | New York, USA

Arend L Mapanawang, Sarah G Mapanawang, Dolfina Galela, Marthein Mocapedua Z, Averous Budiadji,Alexander O Maengkom

STIKES Halmahera, Indonesia Nanomedicine Pharmacy Laboratorium, STIKES Halmahera,Indonesia Lembaga Penelitian dan Pengabdian Pada Masyarakat, STIKES Halmahera, Indonesia

Scientific Tracks Abstracts: J Nanomed Nanotechnol

Abstract:

Cancer is one of the diseases that the death rate is high because it has not found a drug that heals it completely. Researches continue to be developed incorrectly one is to develop a (Zingiberaceae) and leaf pangi (pangiense) vegetables consumed daily in Minahasa North Sulawesi by MTT and HPLC test methods golobe 6.5mg/ml and pangi 150mg/ml performed to see antioxidant activity and anticancer, can be seen the result that encourages use as protection or prevention is consumed as a health supplement either as an antioxidant or serves as a precaution against a variety of free radicals that have the potential to trigger the cells cancer in the body. FTIR test and spectrometer analysis and MTT Test, with the result of comparison of 1307- Fori 7/7 VS MCF-7 with IC50 (μg/ ml) 1307,015 with positive control of cisplatin IC50 (μg/ ml) 8,028. This shows golobe provides low activity but as supplements are very useful for protection or prevention. Likewise with a combination of pangi and golobe (dry simplicia) IC50 (μg/ml) 5860,470. This shows activity is weak but when given each IC50 golobe has more activity strong for cancer activity. At FTIR test leaf pangi has the highest peak 3510,6, intensity 16,36, base (H) 3747,85, base (L) 3497,09, area 141,06, Corona 113,25. Pangi leaves also have activity antioxidant and anticancer and has an antiretroviral activity that the herbs are from the grass become a new hope for prevention and even treatment in the future come.

Biography :

Arend L Mapanawang has completed his Ph.D. from the Department of Pharmacy, College of Health Sciences, Yayasan Medika Mandiri Foundation, Halmahera, Indonesia. He is the Director of College of Health Sciences (STIKES Halmahera), Medika Mandiri Foundation, Halmahera, Indonesia. He is the Head of Internal Medicine Departement of Bethesda Hospital in Tobelo North Halmahera, North Moluccas.

E-mail: arend_mapanawang@gmail.com